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The following on histology and immunohistology of Barrett’s esophagus (BE) includes commentaries on the various
difficulties remaining in reaching a consensus on the definition of BE; the difficulties in the characterization of
intestinal and cardiac mucosa, and in the role of submucosal glands in the development of BE; the importance of a
newmonoclonal antibody to recognize esophageal intestinal mucosa; the importance of pseudo goblet cells; the best
techniques for the endoscopic detection of Barrett’s epithelium; and the biomarkers for identification of patients
predisposed to the development of BE.
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7; cytokeratin 20; CDX2; reflux esophagitis; submucosal glands; Montreal Working Group; Prague criteria; cardiac
mucosa; oxyntic cells; goblet cells; gastroesophageal junction; adenocarcinoma; pseudogoblet cells; esophageal glands;
four-quadrant biopsies; MUC2; villin; Das-1; immunohistochemistry
Concise summaries
• There are still several challenges to achiev-
ing consensus on the definition of Barrett’s
esophagus (BE). The element of proximal ex-
tension must be based on an accurate, repro-
ducible endoscopic identification of the gas-
troesophageal junction (GEJ). All metaplasia
in the columnar lined esophagus may already
be partway on the path to cancer. In addi-
tion, the progression to cancer of patientswith
no goblet cells and goblet cells appears to be
similar. Intestinal metaplasia (IM) of both the
esophagus and the cardia sharemany features,
with respect to expression of certain antigens.
• There is currently no immunohistochemical
marker that is specific to assist in defining
the anatomic site of the biopsy or resection
sample.
• Despite experimental observations on ani-
mals suggesting that BE can develop from an
alternative source in an esophageal environ-
ment made noxious by reflux, they does not
preclude the cell of origin for BE in humans
being derived from the ducts of the submu-
cosal glands (SMGs).
doi: 10.1111/j.1749-6632.2011.06046.x
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• There is not yet consensus on the definition
of BE. The element of proximal extension
must be based on an accurate and repro-
ducible endoscopic identification of the GEJ.
Cardiac mucosa can be abnormal and meta-
plastic and can progress to dysplasia and ade-
nocarcinoma, but the frequency is unknown.
• The type of GEJ adenocarcinomas and the
male:female ratio are different from those
with a profile of Barrett’s mucosa, thus sug-
gestingdifferences in themechanismof cancer
development and the role IM as a marker of
cancer risk.
• Metaplasia of colonic phenotypemay occur at
the distal esophagus in the absence of histo-
logical BE andmay progress to BE. Therefore,
Das-1monoclonal antibody reactivity may be
a useful marker in the identification of BE at
an early stage when chemopreventive strate-
gies may be effective.
• It is essential for the pathologist to be aware of
the presence of “pseudogoblet” cells or gob-
let mimickers that, in the absence of true
intestinal-type goblet cells, do not seem to
have a predictive value in neoplastic progres-
sion. Systematic biopsy appears to be a sound
method for identifying IMdefinedby thepres-
ence of goblet cells. However, if the definition
of BE is revised to include glandular mucosae
without goblet cells, then less comprehensive
biopsy strategies may be as effective in estab-
lishing the diagnosis, and detection of dyspla-
sia will be even more important.
• The use of biomarkers may help confirm
the diagnosis. Problems arise, however, if
these markers are applied indiscriminately
to all esophageal or esophagogastric junction
biopsies endoscopically suspected of being
BE.
• AlthoughCDX2 andMUC-2 are both definite
markers of IM, they cannot be used to identify
patients at risk of BE because they donot seem
to be expressed in any of the earlier steps of
reflux disease.
1. Is the histological presence of IM to
defiantly included in the definition of BE?
Hugh Barr
hugh.barr@glos.nhs.uk
The diagnosis of BE is dependent on endoscopic
and histopathological criteria. The identification of
patients at risk of neoplastic progression with “bad
Barrett’s” is vital. Currently, the guidelines produced
by the American College of Gastroenterology1 and
the British Society of Gastroenterology differ.2
The American College of Gastroenterology defi-
nition states that the change in the distal esophageal
epithelium of any length that can be recognized as
columnar type mucosa at endoscopy and is con-
firmed to have IM by biopsy of the tubular esopha-
gus. These guidelines recognize that the yield of IM
decreases as the segment of columnar lining short-
ens and fewer biopsies are taken. Repeat endoscopy
and biopsy are often necessary to establish the pres-
ence of IM. Very few patients with long segment
Barrett’s have no goblet cells on biopsy. It is also
common not to see these cells in patients with seg-
ments less than 1 cm in length. It is also clear that
intestinalization is heterogeneous and focal.1
The British Society of Gastroenterology defini-
tion states that any portion of the normal squa-
mous lining replaced by a metaplastic columnar ep-
ithelium that is visible macroscopically. To make a
positive diagnosis of a segment of columnar meta-
plasia of any length, itmust be visible endoscopically
above the esophago-gastric junction and confirmed,
corroborated, or in keeping with histology:
(i) Confirmed: native esophageal structures are
present with juxtaposition to metaplastic glan-
dular mucosa, whether intestinalized or not;
(ii) Corroborative: this could potentially still repre-
sent incomplete IM in the stomach;
(iii) In keeping: gastric type mucosa of either fundic
or cardiac type; and
(iv) No evidence: esophageal type squamousmucosa
with no evidence of glandular epithelium.2
Liu et al.3 have shown that of 68 patients with
columnarmetaplasia, 22 patients had no goblet cells
identified, and 46 contained goblet cells in their
biopsies. In both groups, there were chromosomal
and genetic instability, and DNA content abnor-
malities. There were no significant differences be-
tween these cellularDNAabnormalities between the
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Table 1.Progression to cancer of patients with intestinal
metaplasia or not on biopsy
Number of Cancer
patients progression
Kelty et al.4
12 year follow-up
Intestinal metaplasia 379 4.5%
No intestinal metaplasia 309 3.6%
Gatenby et al.5
Registry data
Intestinal metaplasia 612 3.1%
No intestinal metaplasia 322 3.2%
two groups. Both were significantly different from
gastric controls. Thus, all metaplasia in the
columnar-lined esophagus may already be part way
on the path to cancer. In addition, the progression
to cancer of patients with no goblet cells and goblet
cells appears to be similar (Table 1).4,5
It appears that all columnarmetaplasia in the dis-
tal esophagus has neoplastic potential. Guidelines
will need to be formulated in the context with this
new knowledge and guidelines should be harmo-
nized internationally.
2. Can IM in the esophagus be reliably
distinguished from IM in cardiac mucosa?
Melissa P. Upton
mupton@u.washington.edu
Can IM in the esophagus be reliably distinguished
from IM in cardiac mucosa? The answer is some-
times, but not always, for the following reasons.
The precise site where the esophagus ends and
stomach begins cannot always be determined en-
doscopically or histologically. There is controversy
regarding how best to identify theGEJ at endoscopy.
In Japan, the preference is to use the palisade vessels
as the landmark, but this is not reliable in Western
series, which may reflect differences in body habi-
tus of the patients or in endoscopic technique. The
Prague criteria use the reference point of the proxi-
mal extent of the rugal folds, but there are challenges
in interpretation, especially in ultra-short segment
BE,due to irregularity of the squamocolumnar junc-
tion and the motion of the junction in real time
in a living patient. Thus, endoscopic biopsy spec-
imens are provided to pathologists with, at best,
“estimates” of location when taken from the GEJ or
distal esophagus.
What microanatomic features can define the
location of IM detected in biopsy and
endoscopic mucosal resection samples?
Specific microanatomic features are seen in the
esophagus but not in the stomach. These include
SMGs and their ducts, squamous epithelium, and
duplication of the muscularis mucosae.6 Depend-
ing on sampling, identification of these structures
on histology permits the pathologist to locate the
specimen as esophageal. Other histologic features
more often seen in biopsies from esophagus in-
clude multilayered epithelium, the presence of hy-
brid glandswith IMat themucosal surface andother
morphology below, crypt disarray, incomplete IM,
and extensive IM. When a biopsy sample has more
than one of these features, there is increased sen-
sitivity and sensitivity to predict that the biopsy is
from the esophagus; when four to five of these fea-
tures are seen, the sensitivity and specificity of as-
signing location as esophageal are 85% and 95%,
respectively.7
Is there a background of helicobacter pylori
(HP) gastritis?
Biopsies from gastric antrum and body are essen-
tial to evaluate the context of background gastric
histology. “Short-segment” IM at the GEJ in a set-
ting of intestinalized pan-gastritis and HP infection
is likely HP-related cardiac IM rather than related
to chronic reflux, but some patients with HP gas-
tritis may also have reflux esophagitis. Helicobacter
organisms may be seen on hematoxylin and eosin
(H&E) or special stains but might not be detected
in chronic and extensively intestinalized cases.
Is there a difference in expression of
cytokines, comparing esophageal IM with
cardia IM?
Ormsbyandassociates at theClevelandClinicFoun-
dation studied 31 surgical resection or biopsy spec-
imens from long segment BE and 13 gastric cardia
biopsies with IM, obtained by retroflexing the endo-
scope within 5 mm of a normal appearing squamo-
columnar junction.8 They identified a “BE specific
staining pattern” of strong expression of Cytoker-
atin 7 by surface and glandular epithelium, along
with weak superficial CK20 staining. This BE pat-
tern was not seen in any of the gastric IM speci-
mens.8 However, this staining pattern has not been
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consistently reproduced in other hands. Glickman
and associates reported in 2001 a study of cases of
short segment BE, long segment BE, IM at GEJ,
IM in gastric antrum in HP gastritis, normal non-
metaplastic GEJ, and normal antrum. The Barrett’s-
type CK pattern defined by the Ormsby group was
seen in LSBE, SSBE, and IMGEJ, and in 14% of IM
in gastric antrum in HP cases in their hands. El-
Zimaity et al. reported (also in 2001) that eight of
23 patients with cardia IM had theOrmsby “BE pat-
tern.” In a review summarizing results of 16 studies
with 46 comparisons using cytokeratin staining, ap-
proximately half of the studies reported results that
supported the Ormsby finding, but the other half
rejected the specificity of CK7/20 staining to sep-
arate IM of BE from IM of cardia.9 Consequently,
given the variability of reported results, pathologists
in most institutions are not applying these stains in
clinical practice to differentiate esophageal IM from
cardiac IM.
Are there other markers that can assist in
differentiating esophageal IM from cardia IM?
Das-1 antibody recognizes goblet cells in colonic
mucosa, and it can be seen in mucosa of BE even
without goblet cells. It is an interesting marker that
may be an early sign of IM, but it is also seen in
cardiac glands with IM. CDX2 (caudal-type home-
obox 2) is a master switch for intestinalization that
is expressed in BE with and without goblet cells. It
appears to be an early marker of intestinalization
that can be detected before intestinal features, such
as goblet cells or production of acidic mucin, can
be seen on routine histology; however, it is also ex-
pressed in gastric IM. Antibodies against mucins
(MUCs), Hepar-1, CD-10 may be useful for iden-
tification of IM, but they do not improve detection
over histology, and they do not appear to assist in
discerning if a biopsy is from the esophagus or the
cardia. There are many individual studies of var-
ious immunohistochemical markers, summarized
in several recent reviews, and none appears specific
for differentiating esophageal IM from cardia IM.10
In summary, in 2010, IM of both the esophagus
and the cardia share many features, with respect to
expression of certain antigens. There is currently
no immunohistochemical marker that is specific to
assist in defining the anatomic site of the biopsy
or resection sample. Careful histologic examina-
tion, with attention to certain microanatomic fea-
tures, appears to be the most sensitive and specific
method to determine the location of biopsies, and
clear endoscopic-pathologic correlation remains the
gold standard of clinical practice.
3. Is there evidence for a role of the
esophageal SMGs in the origin of BE?
Roy C. Orlando
rorlando@med.unc.edu
BE is an esophageal lesion that develops in the
distal esophagus of patients with reflux esophagi-
tis. In this respect, it is likely a form of adaptive
protection because its biology appears to provide
greater protection against acid injury than does na-
tive esophageal stratified squamous epithelium.11
Among the data that support this scenario are the
greater frequency of the lesion in subjects with gas-
troesophageal reflux disease (GERD) than in the
general population without GERD, its emergence
in distal esophagus in those with reflux esophagi-
tis and in the proximal esophageal segment fol-
lowing esophagectomy in those with esophagogas-
trostomy, and documentation in animal models of
reflux esophagitis showing replacement of eroded
squamous epithelium with Barrett’s specialized
columnar epithelium.12
The origin of the cell(s) that give rise to BE is un-
known. However, since the characteristic morphol-
ogy of BE requires the presence of goblet cells, and
goblet cells are not normally present in any tissue
adjacent to esophageal epithelium, the cell of ori-
gin must be pluripotential and capable of adapting
to the noxious environment. The candidate tissues
fromwhich the pluripotential cell is derived include
(a) gastric cardiac epithelium; (b) esophageal strat-
ified squamous epithelium; and (c) the epithelium
lining the ducts of the esophageal SMGs.
The case for the cell of origin in BE being from the
ducts of the esophageal SMGs include the following:
1. Location: the ducts of the SMGs are widely
distributed along the length of the human
esophagus, as is evident by their visualiza-
tion when dilated in patients with intramural
pseudodiverticulosis;
2. Morphology: the morphology of the ducts of
the SMGs varies from simple columnar in the
lower two-third nearest the acini to stratified
squamous in the upper one-third nearest the
Ann. N.Y. Acad. Sci. 1232 (2011) 76–92 c⃝ 2011 New York Academy of Sciences. 79
Barrett’s esophagus: histology and immunohistology Barr et al.
lumen which indicates that it has the intrinsic
capacity for generation of both squamous and
columnar phenotypes; and13
3. Observation: experimental models of reflux
esophagitis in the canine, an animal whose
esophagus contain SMGs, have shown continu-
ity between the ducts of the SMGs and the sur-
face generation of Barrett’s specialized colum-
nar epithelium.14 Moreover the generation of
BE in this model occurs in the lower esophagus
even when the damaged/resected areas are not
in continuity with gastric mucosa.15
The most challenging observation that argues
against the cell of origin in BE being derived from
the ducts of the esophageal SMGs is that experi-
mental models of reflux esophagitis in the rat, an
animal whose esophagus is devoid of SMGs, have
also been shown to develop Barrett’s specialized
columnar epithelium. While this observations sug-
gests that BE can develop from an alternative source
in an esophageal environment made noxious by re-
flux, it does not preclude the cell of origin for BE in
humans being derived from the ducts of the SMGs.
4. Is there a consensus on the definition
of BE?
David Armstrong
armstro@mcmaster.ca
A diagnosis of BE is predicated on the presence of
metaplastic columnar epithelium, extending proxi-
mally from the GEJ, leading to replacement of the
original esophageal squamous epithelium.1
The criterion that the columnar epithelium
should extend proximally from the GEJ, necessar-
ily excludes columnar islands found in the proxi-
mal esophagus but it should not exclude islands of
columnar epithelium located in the distal esopha-
gus. However, although there is good general agree-
ment on the principle that BE represents columnar
metaplasia, a precise definition remains tantalizing
elusive.1 The diagnosis of BE requires the endo-
scopic identification of an abnormal area of ep-
ithelium in the distal esophagus, but it is generally
agreed that the diagnosis should then be confirmed
histologically.
On this basis, the Montreal working group
proposed the term “endoscopically suspected
esophageal metaplasia” (ESEM) to describe endo-
scopic findings consistent with BE that await histo-
logical evaluation.16 The American College of Gas-
troenterology guidelines state that “BE is a change
in the distal esophageal epithelium of any length
that can be recognized as columnar type mucosa at
endoscopy and is confirmed to have IM by biopsy
of the tubular esophagus.”1
However, there is, by no means, universal agree-
ment that IM is a prerequisite for the diagnosis
of BE,1 and, for this reason, the Montreal working
group proposed that BE be diagnosed when biop-
sies fromESEM show columnar epitheliumwith the
rider that the presence or absence of intestinal-type
metaplasia should also be specified.16
There are several challenges to achieving consen-
sus on the definition of BE. One major challenge is
that it can be difficult to locate the GEJ precisely; if
this cannot be achieved, it will be difficult to know
whether any columnar epithelium has, indeed, been
replaced by squamous epithelium. Another major
challenge arises from uncertainty as to the malig-
nant potential of different types of columnar ep-
ithelium; specifically, there is no consensus as to
whether the absence of intestinal-type metaplasia is
sufficient to conclude that there is negligible risk of
developing esophageal adenocarcinoma.1 The final
major challenge arises because it is clear that there
can be marked disparity between endoscopic find-
ings and histological findings.16
The endoscopic detection of ESEM and a precise
description that includes a standardized measure
of its endoscopic extent16 requires recognition of
the squamocolumnar junction (SCJ) and the GEJ
as well as their location, for example, in relation
to the distance from the incisors or the dental ar-
cade. The importance of accurate and reproducible
endoscopic identification of the GEJ was acknowl-
edged in the development of the Prague C&M Cri-
teria.17 The proximal limit of the gastric folds, the
distal esophageal pinch (attributable to the lower
esophageal sphincter), and the distal limit of the
esophageal palisade vessels18 were all considered as
potential landmarks of the GEJ. In the validation
of the Prague Criteria, the reliability coefficients of
0.88 and 0.78, respectively were reported for iden-
tification of the proximal limit of the gastric folds
and the pinch in the distal esophagus.17 This ex-
cellent inter observer agreement on identification
of the GEJ was not, however, matched in a similar
study that reportedmarkedly lower kappa values for
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identification of the palisade vessels (0.16) and the
tops of the gastric folds (0.12: pre-education; 0.35:
post-education).18
For patients with columnarmetaplasia, the risk of
esophageal adenocarcinoma is greater for thosewho
have intestinal-type metaplasia.1 However, the de-
tection of intestinal-type metaplasia is dependent
upon the extent of the ESEM and on the num-
ber of biopsies taken; it has been proposed that
eight biopsies may be needed to assess adequately
for intestinal-type metaplasia.1 Thus, the absence
of documented intestinal-type metaplasia may not
be sufficient to exclude a diagnosis of BE. Obtain-
ing adequate numbers of biopsies and ensuring that
the biopsies are acquired from the area of interest
can also be a challenge, particularly if the area of
interest is small, as in short segment BE. For ex-
ample, less than one third of biopsies obtained in
a study of patients with reflux disease showed his-
tological features consistent with the area that had
been targeted.19 This, along with regional hetero-
geneity in the columnar epithelium, may explain
the discrepancies, noted previously, between en-
doscopic and histological findings in patients with
ESEM.16
In conclusion, there is not yet consensus on
the definition of BE although there is, perhaps,
agreement that the term, BE, describes colum-
nar metaplasia, extending proximally from the
GEJ to replace esophageal squamous epithelium.16
Histological confirmation that the abnormal endo-
scopic appearances are, indeed, indicative of colum-
narmetaplasia is consistent with this definitionwith
the caveat that the element of proximal extension
must be based on an accurate, reproducible endo-
scopic identification of the GEJ.
The Prague C&M criteria, currently, provide the
best-validated GEJ landmarks, although they are
not infallible;17 however, inter-observer agreement
studies have not, to date, provided adequate support
for the use of other landmarks.18 The biggest bar-
rier to achieving consensus on the definition of BE
relates to the risk of esophageal adenocarcinoma.
If BE is defined as the replacement of esophageal
squamous epithelium by metaplastic columnar ep-
ithelium, it should not be difficult to achieve con-
sensus on the definition although the diagnosis may
still be difficult in individuals with very small ar-
eas of columnar metaplasia. If, however, the defi-
nition of BE encompasses the malignant potential
attributable to the metaplasia, it will be very dif-
ficult to achieve consensus. The number and lo-
cation of biopsies required for an accurate assess-
ment of the cancer risk is unknown; similarly, the
risks attributable to different types ofmetaplasia are
unknown as are the effects of treatment, age, en-
vironmental, and genetic factors. Furthermore, in
practice, the diagnosis is influenced by social factors
such as the patient’s financial or health insurance
status.1 Clearly, BE is important because of the risk
of malignancy; however, if it is defined by this risk,
it will remain very difficult, if not impossible, to
achieve consensus on the definition of BE.
5. Is cardia mucosa always abnormal and
of metaplastic origin? Can it progress to
dysplasia and adenocarcinoma?
Michael Vieth, Helmut Neumann, and
Cord Langner
Vieth.LKPathol@uni-bayreuth.de
Cardia mucosa is rather ill-defined. It consists of
foveolar epithelium and mucous glands but can
contain oxyntic cells as well and differs from pure
oxyntic mucosa by the notion that cardia ep-
ithelium appears rather atrophic. Since no strict
and widely accepted histopathological definition of
cardia mucosa exists, one has to accept cardia mu-
cosa as being kind of a transitional epithelium be-
tween the squamous epithelium of the distal esoph-
agus and the columnar epithelium of the proximal
stomach, which is present in virtually every indi-
vidual. Data available are weak also due to the fact
that there is no precise definition in terms of gross
anatomy. The mean length reported in the liter-
ature varies between 0.314 mm and 1.8 mm,20,21
probably depending on the selected population.
Of note, cardia mucosa may not be detected in
some individuals, but in general it is believed to
lengthen with age and can be found in fetuses, kids,
toddlers, and adults with and without reflux dis-
ease. According to experimental data, development
of a cardia-like mucosa can be induced by reflux
promoting operation in baboons. Moreover, car-
dia mucosa was documented to occur proximal to
the anastomosis after cardia resection in the major-
ity of individuals within a follow-up period of 3–88
months.22 In this study the lengthvariedbetween0.3
and 7 cm.
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Figure 1. Gut regenerative cell lineage on morphogenesis of
columnarmetaplasiawithin the distal esophagus,modified after
Hattori et al.23
The concept of gut regenerative cell lineage in-
cludes stem cell driven regeneration induced by ep-
ithelial injury and followed by the appearance of
deep gastric mucous glands (pyloric type cells) and
foveolar type of cells (gastric surface epithelium).
Together, these two components are nothing else
than cardia-like mucosa. Later on, goblet cells may
appear23 (Fig. 1).
Recently, a thorough literature review demon-
strated that not all Barrett adenocarcinomas showed
goblet cell-containing epithelium right next to the
tumor, but cardia-like epithelium was observed in a
considerable amount of cases.24 There was no sig-
nificant association with the size of the tumor but
with the length of the Barrett’s segment. In addi-
tion, these columnar segments without goblet cells
and without neoplasia show molecular abnormal-
ities similar to goblet cell-containing epithelium,25
indicating that individuals without goblet cells in
a columnar segment may have a risk of malignant
transformation.
Thus, available data are confusing:
• On the one hand, it is possible that cardia ep-
ithelium within the proximal stomach (how-
ever that is defined) represents a physiological
condition; itmay evenbecome longerwith age,
indicating adaptive rather than metaplastic
change.
• On the other, cardia-like epithelium proximal
to the gastro-esophageal junction (however
that is defined) has to be regarded a meta-
plastic condition with risk of malignant trans-
formation (that is much lower than in cases
with goblet cells as it looks at the moment.)
Adopting data on the carcinogenic role of IM
in the stomach to the esophagus, the risk of
malignant transformation of columnar meta-
plasia (in the distal esophagus) with goblet
cells may be at least five to six times higher
compared to cases with columnar metapla-
sia lacking goblet cells, but in fact, we do not
know.
Clinical implications are not clear at the mo-
ment. In particular, we do not know what to do
with individuals that show endoscopic columnar-
lined esophagus but no goblet cells. An inflationary
increase of the diagnosis “BE” is possible.
In conclusion, the questions addressed above can
be answered as follows:
- Yes, cardia mucosa can be abnormal and meta-
plastic, but not in all cases (depending also
on the definition of the gastro-esophageal
junction); and
- Yes, cardia mucosa can progress to dysplasia
and adenocarcinoma, but the frequency is
unknown.
6. What is the significance of microscopic
foci of specialized IM at the GEJ?
Elizabeth L. Wiley
ewiley@uic.edu.
IM is a known risk factor for development of adeno-
carcinoma (AdCa) of distal esophagus, distal stom-
ach, and gallbladder. The degree of risk of AdCa
developing in the setting of IM of the esophagus
varies with the length of esophagus that has un-
dergone columnar metaplasia.26 Long segment BE
has greater risk of AdCa than short segment. Stein26
suggests that ultra-short segment Barrett’s or small
foci of IM at the GEJ, may carry an elevated but
lesser risk of carcinoma than either short segment
and long segment Barrett’s mucosa.
Case reports, such as Gangarsosa’s report of two
patients with foci of IM at the GEJ in which one
developed invasive carcinoma in follow-up, indi-
cate that increased risk of development of AdCa
may exist for patients with small foci of IM at
the GEJ.27 Siewert,28 in his review of 1002 patients
with AdCa of the GEJ found differences in the
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patient population and tumor type by precise tumor
location. AdCa of the distal esophagus (DE) had co-
existing IM in 75%, and nearly 80% of tumors had
intestinal growth pattern. Only 10% of tumors aris-
ing at the GEJ had coexisting IM and more than
half had diffuse type AdCa; but since only 14% of
GEJ tumors were pT1 tumors, any preexisting foci
of IM may have been overrun by the carcinomas.
Therewas also adifference in thepatient population.
There was a 9:1 male to female ratio for DE AdCa,
whereas GEJ tumors had a 5.4:1 male to female
ratio.
Tytgat,29 in his review of several studies, found
a 6 to 24% incidence of IM at the GEJ in symp-
tomatic patients undergoing upper gastrointestinal
endoscopy. In the same group of studies, short seg-
ment BE had a slightly lower incidence (2–12%).
Although Tytgat29 suggests that the incidence of IM
at the GEJ may be higher in the general population,
the exact difference has not been established. At the
author’s university medical center, a large group of
patients undergo upper endoscopy for complaints
other than GERD. Review of pathology for Qual-
ity Assurance showed that in a one-year period, 2%
of patients without complaints of gastritis, GERD,
or history of Barrett’s had a new diagnosis of IM
on biopsy of the DE, and IM was found in 9% of
those who were biopsied at the GEJ. For compari-
son, 5% of DE, and 7% of GEJ biopsies of patients
with symptoms of GERD had newly diagnosed IM,
and 4% of DE and 12% of GEJ biopsies of patients
with symptoms of gastritis were diagnosed with
IM. Eleven AdCas were diagnosed during the same
one-year period, only two of which were associated
with a history of Barrett’s, and none of the remain-
ing nine had presenting complaints of GERD or
gastritis.
In summary, there is a low incidence of IM in the
distal esophagus and at the GEJ junction. This in-
cidence varies with symptoms; patients with GERD
have a higher incidence of IM in the DE, whereas
patients without symptoms of GERD have a higher
incidence of IM at the GEJ. Indirect evidence shows
an elevated risk of AdCa for patients with IM at the
GEJ, but the degree of elevation of risk is unknown.
The type of GEJ AdCa and the male to female ra-
tio are different than those with a profile of Barrett’s
mucosa;2 this suggests differences in themechanism
of cancer development and the role IM as a marker
of cancer risk.
7. Is the monoclonal antibody, mAb Das-1
likely to help in early recognition of IM of
the esophagus?
Kiron M. Das, Octavia E. Pickett-Blakely,
Manisha Bajpai, and Peter S. Amenta
daskm@umdnj.edu
Adenocarcinoma of the esophagus (EAC) has the
highest rate of increase among all cancers in the
U.S. and in the Western World. The incidence has
increased approximately 400%over the last 25 years.
Barrett’s epithelium, a specialized columnar meta-
plasia of the distal esophagus/gastro-esophageal
junction (GEJ) from chronic GERD, is a precursor
to EAC.
Chronic gastritis from H. Pylori leads to gastric
intestinal metaplasia (GIM), which predisposes to
gastric cancer, which is a leading cause of cancer-
related deaths in Asian countries. There appears
to be a special phenotype known as incomplete or
colonic phenotype (also known as Type II or Type
III) that is strongly associated with Barrett’s epithe-
lium/EAC and GIM/gastric carcinoma.30,31 Early
detection of Barrett’s epithelium and GIM is es-
sential to identify high risk patients with chronic
GERD and chronic gastritis to institute appropriate
surveillance and treatment.
We developed a monoclonal antibody named
mAb Das-1 (also called 7E12H12, IgM isotype)
that reacts with the colonic epithelium but not
with any other gastrointestinal tract epithelium; in-
cluding columnar epithelium of small intestine and
stomach and squamous epithelium of the esoph-
agus (Fig. 2).32 However, mAb Das-1 reacts with
Barrett’s epithelium and adenocarcinoma arising
from Barrett’s epithelium with 95% sensitivity and
100% specificity (Fig. 2).30 It does not react with
normal esophageal or gastro-esophageal junction
mucosa. This has been confirmed by three indepen-
dent groups of investigators4 who reported a 90–
100% sensitivity and specificity ofmAbDas-1 in the
detection of Barrett’s epithelium. Subsequently, we
demonstrated that mAb Das-1 can detect metapla-
sia before the appearance of histological Barrett’s ep-
itheliumsuggesting the existenceof a “Pre-Barrett’s”
stage.
IM of the stomach can be divided into com-
plete or small intestinal and incomplete or colonic
type (Type II or III) based on the staining pattern
with alcian blue/high iron diamine (AB/HID) and
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Figure 2. (A) and (B) are serial sections of the biopsy specimen from a patient with BE. (A) H&E stain showing squamo-columnar
junctional mucosa from the EGJ with columnar metaplasia with presence of goblet cells. (B) mAb Das-1 reactivity is present in all
the glands, including both goblet and nongoblet cells. Squamous epithelium is identified by (∗) that did not stain with mAb Das-1.
(C) and (D) show immunoperoxidase staining of colon (C) and small intestine (D), respectively, as positive and negative control for
mAbDas-1. mAbDas-1 reactivity is restricted to colon epithelium, both goblet and absorptive cells. Small-intestinal epithelium did
not react with mAb Das-1. Serial sections of formalin fixed paraffin embedded biopsy tissue from a patient with gastric intestinal
metaplasia (GIM) without carcinoma (E & F) and another patient with gastric carcinoma (G and H). Hematoxylin-eosin staining
(E) and (G) and immunoperoxidase assay with mAb Das-1 (F and H). mAb Das-1 stained both goblet cells (shorter arrow) and
metaplastic nongoblet cells (longer arrow) in the glands (F). Intense cytoplasmic staining of the cancer cells with mAb Das-1 is
clearly evident in the gastric carcinoma (H) (original magnification 160×).
differences in goblet cell glycoprotein composition.
The complete or colonic phenotype appears to carry
the highest preneoplastic potential. The colonic
phenotype of metaplasia as detected by mAb Das-1
has been reported in stomach, particularly associ-
ated with gastric carcinoma.31 Ninety-three percent
of gastric intestinal metaplasia that stained positive
for mAb Das-1 was associated with gastric cancer.
Although normal small intestinal epithelium does
not react with mAb Das-1, small intestinal cancer
reacts with the antibody.33 These findings demon-
strate the potential of mAbDas-1 antibody to detect
preneoplastic changes in the esophagus, stomach,
and small intestine.
We rather serendipitously discovered the reactiv-
ity of mAb Das-1 against Barrett’s epithelium and
demonstrated that this antibody reactswithBarrett’s
epithelium with high sensitivity and specificity.30
The reactivity in Barrett’s epithelium is present in
the goblet cells (GC), as well as in nongoblet cells30
in the same glands (Fig. 2B). The reactivity to mAb
Das-1 indicates that the metaplastic change in Bar-
rett’s epithelium is of colonic phenotype, includes
the entire gland, and is independent of the presence
ofmorphologically evident typical goblet cells.mAb
Das-1 also reacts with 100% of adenocarcinoma of
the esophagus, but does not react with squamous
cell carcinoma.30
Early detection of columnar metaplasia at the
distal esophagus/GEJ in GERD in the
absence of histological Barrett’s epithelium
In several studies, we and others demonstrated the
presence of mAb Das-1 reactive cells at the dis-
tal esophagus in patients with GERD symptoms in
the absence of histological Barrett’s epithelium. The
mAb Das-1 reacted with “cardia-type” columnar
epithelium located at the distal esophagus, and not
with gastric cardia-epithelium. In one study, mAb
Das-1 reactivity in the IM of the gastroesophageal
junction (IM-GEJ) was reported to be 100%.34 Fol-
lowing complete histological ablation of Barrett’s
epitheliumby laser therapy, persistence ofmAbDas-
1 reactivity was found to be a better predictor of
recurrence.35 One hundred percent of cardia-type
mucosa reactive to mAb Das-1 after complete “en-
doscopic and histologic ablation” of Barrett’s ep-
ithelium had recurrence of Barrett’s epithelium.
We recently completed a prospective study of 262
patients with chronic GERD symptoms who had
endoscopy and 4-quadrant biopsies from the dis-
tal esophagus/GEJ. Sixteen percent of these patients
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Figure 3. Serial sections of a biopsy specimen from squamo–columnar junction of a patient with initial biopsy that shows
mAb Das-1 positive (panel B), but histology with mild esophagitis only (panel A). Panels (C) and (D) show repeat endoscopic
biopsy specimen from three-and-a-half years later, showing BE with severe dysplasia (identified by the rectangle). The patient
subsequently had endomucosal resection. (E)–(H) show H&E, mAb Das-1, Cdx-2, and AB/HID stains, respectively. ∗Indicates
squamous epithelium.
withGERDhadmAbDas-1 reactivitywithouthisto-
logical evidence of Barrett’s epithelium/IM.A subset
of 11 of these mAb Das -1 positive patients had his-
tological diagnosis of esophagitis (n = 8) and three
had reportedly normal mucosa. These patients were
prospectively followed for up to four years with se-
rial upper endoscopies at one to three year inter-
vals. Of the 11 patients with mAb Das-1 reactiv-
ity in the absence of IM, two developed Barrett’s
epithelium. One of the two patients that devel-
oped Barrett’s epithelium subsequently developed
Barrett’s epithelium with high grade dysplasia after
three and a half years (Fig. 3). These data together
suggest that metaplasia of colonic phenotype may
occur at the distal esophagus in the absence of his-
tological Barrett’s epithelium and may progress to
Barrett’s epithelium. Therefore, mAb Das-1 reactiv-
ity may be a useful marker in the identification of
BE at an early stage when chemopreventive strate-
gies may be effective. Immunoperoxidase staining
with mAb Das-1 can be performed easily with a
serial histologic sections parallel to H&E.
These in vivo observations are also supported by
the novel in vitromodel we recently reported.35 Ex-
posure of the hTERT transfected, immortalized, be-
nign Barrett’s cell line (BAR-T) to HCL (pH4) (A)
and bile salt (200 !m glycochenodroxycholic acid)
(B) for 5min/day for two weeks, BAR-T cells show a
two- to threefold increase in colonic phenotype cells
that react to mAb Das-1.36 Furthermore, long-term
daily exposure (65 weeks) to A + B causes trans-
formation of benign BAR-T cells to neoplastic cells
as evident by foci formation, distinct colonies in
soft agar and formation of tumor in nude (nu/nu)
mice.37
8. What is the frequency of cells showing a
similarity with intestinal goblet cells on
biopsies and their influence on false
diagnosis of Barrett’s metaplasia?
Ana Bennett
benneta@ccf.org
Not uncommonly, cardiac-type gastric mucosamay
contain foveolar cells with barrel-shaped or dis-
tended cytoplasmic vacuoles resembling goblet cells.
These distended gastric foveolar cells are also
called “pseudogoblet” cells and represent a poten-
tial source of error in the diagnosis of BE. Fortu-
nately, these mimics usually stain less intensely than
true goblet cells with Alcian blue at pH 2.5, and
pseudogoblet cells are generally arranged in linear
contiguous stretches without intervening colum-
nar cells.38–40 Pseudogoblet cells contain a hazy,
ground glass appearance to their cytoplasmicmucin
(Fig. 4). Esophageal glands and gland ducts are
another source of confusion about Alcian blue-
positive cells. If they are sampled at all, these glands
and ducts are usually located within the deeper
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Figure 4. Pseudogoblet cells contain a hazy, ground glass appearance to their cytoplasmic mucin.
portions of endoscopic biopsies in either the lamina
propria or submucosa. They are characteristically
intensely and diffusely Alcian blue positive at pH
2.5, but differentiation from true columnar meta-
plasia is not difficult because esophageal glands have
a rounded or lobular configuration similar tominor
salivary glands, and are located deep in the mucosa
and submucosa. The ducts draining these glands
may have a mucinous or transitional-type epithe-
liumandmay also containAlcian blue-positive cells.
The contiguous Alcian blue-positive cells within a
duct-like structure and/or coexistent transitional-
type epithelium and/or identification of the ac-
tual esophageal glands being drained by the duct,
usually permit distinction from Barrett’s metaplas-
tic epithelium.
A correct diagnosis is essential to spare patients
life-long surveillance anxiety and avoid possible in-
ability to obtain medical insurance. Few data are
available on the frequency of pseudogoblet cells in
esophageal biopsies. In a recent study,41 initial biop-
sies of 78 patients with diagnosis of BE, negative for
dysplasia and a mean follow-up of 72 months were
reviewed, intestinal-type goblets cells were identi-
fied in 56 (72%) of the cases. In the remaining
twenty-twocases, onlypseudogoblet cellswere iden-
tified in 12 cases and 10 cases, although originally
diagnose as BE did not show either pseudogob-
let cells or true goblet cells. Furthermore, only the
presence of intestinal-type goblet cells was associ-
ated with significant risk of dysplasia (P = 0.008).
One patient with pseudogoblet cells was diag-
nosed with dysplasia after 146 months of follow-up
compared with 21 (35%) patients with intestinal-
type goblet cells that developed dysplasia on
follow-up.41
It is essential for the pathologist to be aware of
the presence of “pseudogoblet” cells or goblet mim-
ickers, which in the absence of true intestinal-type
goblet cells do not seem to have a predictive value
in neoplastic progression.
9. Are systematic four-quadrant biopsies
the safest way to detect Barrett’s
epithelium?
James J. Going
gqxa02@udcf.gla.ac.uk
Paull et al.43 described three types of columnar mu-
cosa in Barrett’s esophagus (BE), proximal to the
lower esophageal sphincter: one resembling gas-
tric fundic mucosa with parietal and chief cells;
one resembling gastric cardia mucosa, with mucous
glands; and a distinctive type with mucous glands
and goblet cells.
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Figure 5. Intestinalmetaplasia with goblet cells: until recently,
this has been taken as defining feature in Barrett’s esophagus.
If future work sustains the proposal that cancer risk may be
significantly elevated without goblet cells, their importance as a
risk marker will diminish.
The answer to the title question depends on
whethermucosa with IMdefined by goblet cells (IM
with GC) is regarded as essential for the diagnosis of
BE (Fig. 5). That IMwith goblet cells is essential for a
diagnosis of BEhas been generally held in theUnited
States and widely, but not universally, in the UK and
elsewhere, including Japan. This definition is moti-
vated by the belief in a strong association between
IMwith goblet cells and dysplasia and increased risk
of progression to invasive adenocarcinoma; and that
glandular metaplasia alone, in the absence of goblet
cells, is not associated with the same elevated cancer
risk. After a number of years during which this view
has generally been accepted, the evidence for it has
begun to be questioned.
Notably, Takubo et al.44 describe a weaker than
expected association between IM with goblet cells
andearlyBarrett’s adenocarcinoma,whichappeared
in their cases to arise on a background of cardia-like
glandular mucosa. In addition, Odze et al.45 have
pointed out that even in the absence of goblet cells,
there may be evidence of intestinal differentiation,
including expression of intestinal markers MUC2,
DAS1,CDX2, andVillin. Also, recent studies suggest
that chromosomal and DNA content abnormalities
are not different between metaplastic esophageal
glandular mucosa with and without goblet cells, in
keeping with a risk of neoplastic progression similar
in both.
In the West of Scotland, it is rare for a long seg-
ment Barrett’s esophagus (LSBE) patient to have
no histological IM with goblet cells.46 Of thirty-
two randomly selected and systematically biopsied
LSBE patients, the cumulative probability of IM be-
ing present at any level was about 90%, and 100%
overall. On the other hand, other studies have found
a lower prevalence of IM, which may be a function
of age.
If the endoscopist thinks there is a long seg-
ment Barrett’s mucosa, and the histopathologist can
demonstrate glandular mucosa in a locus consid-
ered to be esophageal by the endoscopist but no IM,
often, but not always, the reason will be too few
biopsies. For as long as IM with GC is taken to de-
fine BE, a minimum of 4-quadrant biopsies will be
required before BE could be excluded. Things are
less clear cut in SSBE, but, here too, a 4-quadrant
biopsy would be a reasonable diagnostic minimum,
except perhaps in the case of an isolated mucosal
tongue.
This question is related to whether or not sys-
tematic 4-quadrant biopsy is the most effective way
to diagnose dysplastic Barrett’s mucosa, not Bar-
rett’s per se. A (nonrandomized) comparison47 of
two biopsy approaches at Glasgow Royal Infirmary
over nine years began in 1995 when a group of sur-
geons adopted a systematic biopsy approach, while
medical gastroenterologists adhered to nonsystem-
atic protocols. Two demographically similar cohorts
each of 180 patients were compared. Prevalance of
dysplasia was 18.9%with systematic biopsy but only
1.6% with random biopsy. Only 2.2% of system-
atically biopsied patients developed incident LGD
after a median of 62 months compared with 6.6%
of nonsystematically biopsied patients after a me-
dian of 36 months. These data are in keeping with
a relatively low incidence of genuinely new dyspla-
sia: most BE patients have had BE for a long time
by the time of their index endoscopy. The relatively
high prevalence of dysplasia is not unexpected given
the high incidence of esophegeal adenocarcinoma in
Scotland.
In summary, systematic biopsy appears to be a
sound method for identifying IM defined by the
presenceof goblet cells in columnar-lined esophagus
(BE). However, if the definition of BE is revised
to include glandular mucosae without goblet cells,
then less comprehensive biopsy strategies may be as
effective in establishing thediagnosis; if so, detection
of dysplasia (or a validated surrogate risk marker)
will be even more important.
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10. Can the exact role of biomarkers for the
diagnosis of BE be defined?
Mamoun Younes and Helen H. Wang
myounes@bcm.edu
BE, or Barrett’s metaplasia, is a condition in which
the normal squamous lining of the esophagus is
replaced by columnar epithelium. Paul and his
colleagues classified BE on the basis of histologic
appearance into three types: cardiac, fundic, and
specialized columnar with intestinal type goblet
cells. However, only the intestinal type with gob-
let cells has so far been definitively associated
with increased risk of progression to esophageal
adenocarcinoma. Currently, in the United States,
histologic documentation of intestinal type colum-
nar epithelium with goblet cells is required for the
diagnosis of BE.
The diagnosis of BE is made by identifying
intestinal-type goblet cells on routine hematoxylin
and eosin (H&E) stained sections of esophageal
biopsies. Several molecular markers have been
shown to be expressed in BE by immunohistochem-
istry (IHC); these include MUC2,48 which stains
the goblet cells; hepatocyte antigen,49 which stains
the absorptive cells; villin,50 which stains the brush
border that incidentally may be lacking in some
cases of BE; Das-1,51 which stains goblet cells; and
CDX2,52 which stains cells with intestinal differ-
entiation including goblet and absorptive cells. As
expression of these markers was found to correlate
very well with “IM” in BE, their clinical utility is
limited.
In a few cases, pathologists whomay not feel con-
fident making a diagnosis of BE because of a sub-
optimal H&E stain, orientation of the biopsy tis-
sue, quality of the section preparation, or presence
of rare cells that are equivocal for being intestinal-
type goblet cells, the use of biomarkers may help
confirm the diagnosis. Problems arise, however, if
these markers are applied indiscriminately to all
esophageal or esophagogastric junction biopsies en-
doscopically suspected of being BE. Figure 1 illus-
trates two such examples. In Figure 6A, IHC for
CDX2 shows scattered cells that slightly resemble,
but are not typical of full-blown intestinal-type gob-
let cells (arrows). Here, positive nuclear staining
for CDX2 confirms an “intestinal” phenotype. In
Figure 6B, none of the columnar epithelial cells at
the squamo–columnar junction even slightly resem-
Figure 6. Immunohistochemical staining for CDX2 in biop-
sies taken from the esophagogastric junction. (A)Positive strong
nuclear staining in columnar epithelial cells including cells sus-
pected of being goblet cells (arrows). (B) Strong nuclear staining
in columnar cells without any goblet cells or any cells remotely
resembling goblet cells. Immunoperoxidase stainingwith hema-
toxylin counterstaining, 20× objective. (Microscope condenser
removed for better delineation of cell membranes to demon-
strate shapes of cells).
ble goblet cells, yet all of these cells are strongly
positive for CDX2. Although these cells may very
well be “pregoblets” and may, with time, become
goblet cells, this is just speculative at the present
time. Almost all patients who have esophageal biop-
sies to rule out BE are symptomatic, and do re-
ceive treatment, medical or surgical, for GERD.
Therefore, it will be extremely difficult to know
the natural history of CDX2 biopsies without gob-
lets, as this will be altered by intervention (med-
ical or surgical), and one would expect that since
reflux is thought to be the cause of CDX2 expres-
sion, adequate treating of GERD, at least in the-
ory, should reverse CDX2 expression or should
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prevent the CDX2-positive cells from progressing
to a goblet phenotype. “Reversal” of established
BE with goblet cells with medical treatment has
been reported. In one study, CDX2 expression in
biopsies of columnar-lined esophagus without gob-
let cells was found to predict the finding of gob-
let cells in a second set of biopsies from the same
patients (taken either before or after the CDX2-
positive biopsies).53 In the same study, however,
24% of patients with CDX2-positive biopsies with-
out goblet cells had no goblet cells in a second set of
biopsies.53 Because patients with BE are subjected
to life-long surveillance and biopsy, anxiety about
their increased chances of getting esophageal cancer,
cost, and adverse effects of somemodalities to treat-
ing or eradicating BE, and increased health and life
insurance premiums, and because most follow-up
studies so far have shown no significant association
between columnar-lined epithelium without goblet
cells and esophageal cancer, strong evidence of asso-
ciation between CDX2-positive nongoblet cell CLE
and esophageal cancer from large-scale prospective
studies is required before labeling these patients as
having BE.
11. What is the value of molecular markers
(CDX2, MUC2, and CK7/20) for
identification of patients predisposed to
the development of BE?
Antonio Taddei, Giancarlo Freschi, Maria Novella
Ringressi, Duccio Rossi Degli’Innocenti, Francesca
Castiglione, and Paolo Bechi
antonio.taddei@unifi.it
Homeobox protein CDX2 is encoded by the CDX2
gene. In humans, this protein is a caudal homeobox
transcription factor, which is involved in the mod-
ulation of complex signaling pathways and tran-
scription processes, important both for embryonic
development and the homeostasis of adult tissues.
Although CDX2 role in BE is not completely under-
stood, it is noticeable that CDX2 is not expressed
in the normal squamous esophageal epithelium,
whereas it has been shown to be highly expressed
in BE.54
Mucins are also widely secreted in the gastroin-
testinal tract, with distinct composition patterns in
the different locations. Among mucins, mucin 2
(MUC2) is prominent in the gut, where it is mainly
Figure 7. Preliminary data showing expression of CDX2 (A), MUC-2 (B), CK7 (C) and CK20 (D) in BE subjects (see text on p. 12
in question 11).
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secreted from goblet cells of the epithelial lining into
the lumen of the large intestine.55
Cytokeratins (CK) form the building blocks for
the intermediate filaments, which contribute to cell
cytoskeleton formation. There are variable patterns
of expression of cytokeratins in epithelial cells de-
pending on the type, location, and differentiation of
epithelium. CK7/20 profiles are considered relevant
for the diagnosis of some diseases of the gastroin-
testinal tract. CK20 is commonly used as a marker
of intestinal differentiation. It is widely expressed
on the surface and crypt epithelium of the nor-
mal colon and small intestine. In the stomach, its
expression is limited to the surface foveolar epithe-
lium (no gastric gland/pit expression). In the esoph-
agus, CK7 specific staining is only detectable in the
superficial layers of the squamous epithelium,
whereas in columnar metaplasia, increased expres-
sion is shown more deeply throughout the crypts
and the glands.
It has been claimed that a specific staining
pattern reliably distinguishes intestinal from the
cardial and oxyntic metaplasia.56 This so-called
Barrett’s pattern is characterized by CK20 super-
ficial staining and diffuse and strong CK7 stain-
ing and has been demonstrated both in long and
short segment BE.56 More recently, the presence
of a CK7/20 Barrett’s pattern has been confirmed,
its presence in ultrashort segment BE has been
demonstrated.57
Wehave preliminary data showing indicating that
CDX2 was absent in all the patients both of normal
epitheliumand the esophagitis groups (unpublished
data).On the contrary, it was highly expressed inBE:
in this group of biopsies a strong nuclear staining
was observed (Fig. 7A).MUC2 had exactly the same
behavior, it was absent both in normal epithelium
and in the esophagitis groups, whereas it was well
expressed in BE: in this group of biopsies a strong
cytoplasmatic staining was shown (Fig. 7B). CK7
and Ck20 expression showed a distribution that
differed from CDX2 and MUC2; their expression
(similar for CK7 and CK20) was evident in all three
groups patients. However, their expression was sig-
nificantly (P = 0.023) greater in BE than in normal
epithelium and esophagitis groups (Fig. 7C & 7D,
respectively). It must be stressed that none of the
patients in the group with CK7/20 expression de-
veloped BE after a five-year follow-up (unpublished
data).
In conclusion, although CDX2 and MUC2 are
both a definite marker of IM, they cannot be used to
identify the patients at risk of BE, since they do not
seem to be expressed in any of the patients earlier
steps of reflux disease. Moreover, CK7/20 in spite
of increased expression in BE than in normal ep-
ithelium and esophagitis, do not seem to identify
those patients who will develop BE. Therefore, on
the basis of this preliminary experience, this panel
of immunohystochemical markers, seems certainly
useful for BE identification but not to predict its
occurrence.
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